SVRA
HealthcareSavara Inc.
$5.80
+$0.16 (+2.84%)
Jan 5, 2026
Price History (1Y)
Analysis
Savara Inc. is a healthcare-focused biotechnology company with a market capitalization of $1.18 billion and 59 employees. The firm operates within the sector of Healthcare and industry of Biotechnology. The financial health of Savara Inc. indicates significant losses, with net income totaling -$115,645,000 in the trailing twelve months (TTM) and an EBITDA of -$120,388,000. Free cash flow is also negative at -$55,260,752. However, the company's balance sheet shows a substantial amount of cash, totaling $124.92 million, while debt stands at $29.83 million. Valuation metrics are notable for their negative values, with a forward P/E ratio of -14.50 and an EV/EBITDA of -10.52. The price to book value is 12.95, indicating that the company's stock price may be considered overvalued relative to its assets.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $1.18B
- P/E Ratio
- N/A
- 52-Week High
- $7.00
- 52-Week Low
- $1.89
- Avg Volume
- 2.58M
- Beta
- 0.28
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 59